Crizotinib (Xalkori®) for first line ALK+ NSCLC

Assessment Status Rapid Review complete
Drug Crizotinib
Brand Xalkori®
Indication For the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Assessment Process
Rapid review commissioned 06/02/2017
Rapid review completed 24/04/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended.